Vertex Receives CHMP Opinion For KAFTRIO In Combination With Ivacaftor For Children With Cystic Fibrosis Ages 2 Through 5
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its drug KAFTRIO, in combination with ivacaftor, for treating children aged 2-5 with cystic fibrosis. If approved, over 1,200 children could be eligible for this treatment.
September 15, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vertex's drug KAFTRIO has received a positive CHMP opinion for treating cystic fibrosis in children aged 2-5. This could potentially expand the drug's market by over 1,200 patients.
The positive opinion from CHMP for Vertex's drug KAFTRIO is a significant step towards regulatory approval. If approved, it could expand the drug's market by over 1,200 patients, which could potentially increase Vertex's revenues and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100